Fulfilling the Promise of Breathomics: Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers

Paul Brinkman; Michael Wilde; Waqar Ahmed; Ran Wang; Marc van der Schee; Shahd Abuhelal; Chad Schaber; Danen Cunoosamy; Graham W Clarke; Anke H Maitland-van der Zee; Sven-Erik Dahlén; Salman Siddiqui; Stephen J Fowler

doi:10.1164/rccm.202305-0868tr

Fulfilling the Promise of Breathomics: Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers

Paul Brinkman
, Michael Wilde
, Waqar Ahmed
, Ran Wang
, Marc van der Schee
, Shahd Abuhelal
, Chad Schaber
, Danen Cunoosamy
, Graham W Clarke
, Anke H Maitland-van der Zee
, Sven-Erik Dahlén
, Salman Siddiqui
, Stephen J Fowler

Amsterdam UMC - Locatie AMC, Department of Respiratory Medicine, Amsterdam, North Holland, Netherlands.
University of Manchester
Manchester University NHS Foundation Trust
Owlstone Medical Ltd, Medical Scientific Advisory Board, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland.
Imperial College London
Owlstone Medical Ltd, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland.
Sanofi Research and Development Center Cambridge
AstraZeneca R&D Mölndal, Goteborg, Sweden.
Karolinska Institutet

Research output: Contribution to journal › Review article › peer-review

8 Downloads (Pure)

Abstract

The exhaled breath represents an ideal matrix for non-invasive biomarker discovery, and exhaled metabolomics have the potential to be clinically useful in the era of precision medicine. In this concise translational review we will specifically address volatile organic compounds in the breath, with a view towards fulfilling the promise of these as actionable biomarkers, in particular for lung diseases. We review the literature paying attention to seminal work linked to key milestones in breath research; discuss potential applications for breath biomarkers across disease areas and healthcare systems, including the perspectives of industry; and outline critical aspects of study design that will need to be considered for any pivotal research going forward, if breath analysis is to provide robust validated biomarkers that meet the requirements for future clinical implementation.

Original language	English
Pages (from-to)	1079-1090
Number of pages	12
Journal	Am J Respir Crit Care Med
Volume	210
Issue number	9
Early online date	18 Jun 2024
DOIs	https://doi.org/10.1164/rccm.202305-0868tr
Publication status	Published - 18 Jun 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine

Keywords

Biomarkers/analysis
Breath Tests/methods
Exhalation/physiology
Humans
Lung Diseases/diagnosis
Metabolomics/methods
Volatile Organic Compounds/analysis
technology readiness level
volatile organic compounds
precision medicine
biomarker
breath tests

Access to Document

10.1164/rccm.202305-0868tr

3TR_AJRCCM_CTR_Revison3_20240416_SUBMIT_cleanAccepted author manuscript, 1.12 MB

Cite this

Brinkman, P., Wilde, M., Ahmed, W., Wang, R., van der Schee, M., Abuhelal, S., Schaber, C., Cunoosamy, D., Clarke, G. W., Maitland-van der Zee, A. H., Dahlén, S.-E., Siddiqui, S., & Fowler, S. J. (2024). Fulfilling the Promise of Breathomics: Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers. Am J Respir Crit Care Med, 210(9), 1079-1090. https://doi.org/10.1164/rccm.202305-0868tr

@article{36c9ee4643114662a07dae7a324c9f6c,

title = "Fulfilling the Promise of Breathomics: Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers",

abstract = "The exhaled breath represents an ideal matrix for non-invasive biomarker discovery, and exhaled metabolomics have the potential to be clinically useful in the era of precision medicine. In this concise translational review we will specifically address volatile organic compounds in the breath, with a view towards fulfilling the promise of these as actionable biomarkers, in particular for lung diseases. We review the literature paying attention to seminal work linked to key milestones in breath research; discuss potential applications for breath biomarkers across disease areas and healthcare systems, including the perspectives of industry; and outline critical aspects of study design that will need to be considered for any pivotal research going forward, if breath analysis is to provide robust validated biomarkers that meet the requirements for future clinical implementation.",

keywords = "Biomarkers/analysis, Breath Tests/methods, Exhalation/physiology, Humans, Lung Diseases/diagnosis, Metabolomics/methods, Volatile Organic Compounds/analysis, technology readiness level, volatile organic compounds, precision medicine, biomarker, breath tests",

author = "Paul Brinkman and Michael Wilde and Waqar Ahmed and Ran Wang and \{van der Schee\}, Marc and Shahd Abuhelal and Chad Schaber and Danen Cunoosamy and Clarke, \{Graham W\} and \{Maitland-van der Zee\}, \{Anke H\} and Sven-Erik Dahl{\'e}n and Salman Siddiqui and Fowler, \{Stephen J\}",

year = "2024",

month = jun,

day = "18",

doi = "10.1164/rccm.202305-0868tr",

language = "English",

volume = "210",

pages = "1079--1090",

journal = "Am J Respir Crit Care Med",

issn = "1535-4970",

number = "9",

}

Brinkman, P, Wilde, M, Ahmed, W, Wang, R, van der Schee, M, Abuhelal, S, Schaber, C, Cunoosamy, D, Clarke, GW, Maitland-van der Zee, AH, Dahlén, S-E, Siddiqui, S & Fowler, SJ 2024, 'Fulfilling the Promise of Breathomics: Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers', Am J Respir Crit Care Med, vol. 210, no. 9, pp. 1079-1090. https://doi.org/10.1164/rccm.202305-0868tr

TY - JOUR

T1 - Fulfilling the Promise of Breathomics

T2 - Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers

AU - Brinkman, Paul

AU - Wilde, Michael

AU - Ahmed, Waqar

AU - Wang, Ran

AU - van der Schee, Marc

AU - Abuhelal, Shahd

AU - Schaber, Chad

AU - Cunoosamy, Danen

AU - Clarke, Graham W

AU - Maitland-van der Zee, Anke H

AU - Dahlén, Sven-Erik

AU - Siddiqui, Salman

AU - Fowler, Stephen J

PY - 2024/6/18

Y1 - 2024/6/18

N2 - The exhaled breath represents an ideal matrix for non-invasive biomarker discovery, and exhaled metabolomics have the potential to be clinically useful in the era of precision medicine. In this concise translational review we will specifically address volatile organic compounds in the breath, with a view towards fulfilling the promise of these as actionable biomarkers, in particular for lung diseases. We review the literature paying attention to seminal work linked to key milestones in breath research; discuss potential applications for breath biomarkers across disease areas and healthcare systems, including the perspectives of industry; and outline critical aspects of study design that will need to be considered for any pivotal research going forward, if breath analysis is to provide robust validated biomarkers that meet the requirements for future clinical implementation.

AB - The exhaled breath represents an ideal matrix for non-invasive biomarker discovery, and exhaled metabolomics have the potential to be clinically useful in the era of precision medicine. In this concise translational review we will specifically address volatile organic compounds in the breath, with a view towards fulfilling the promise of these as actionable biomarkers, in particular for lung diseases. We review the literature paying attention to seminal work linked to key milestones in breath research; discuss potential applications for breath biomarkers across disease areas and healthcare systems, including the perspectives of industry; and outline critical aspects of study design that will need to be considered for any pivotal research going forward, if breath analysis is to provide robust validated biomarkers that meet the requirements for future clinical implementation.

KW - Biomarkers/analysis

KW - Breath Tests/methods

KW - Exhalation/physiology

KW - Humans

KW - Lung Diseases/diagnosis

KW - Metabolomics/methods

KW - Volatile Organic Compounds/analysis

KW - technology readiness level

KW - volatile organic compounds

KW - precision medicine

KW - biomarker

KW - breath tests

UR - https://pearl.plymouth.ac.uk/gees-research/955/

U2 - 10.1164/rccm.202305-0868tr

DO - 10.1164/rccm.202305-0868tr

M3 - Review article

C2 - 38889337

SN - 1535-4970

VL - 210

SP - 1079

EP - 1090

JO - Am J Respir Crit Care Med

JF - Am J Respir Crit Care Med

IS - 9

ER -

Fulfilling the Promise of Breathomics: Considerations for the Discovery and Validation of Exhaled Volatile Biomarkers

Abstract

UN SDGs

ASJC Scopus subject areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this